Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Expenses: 2009-2024

Historic Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $31.0 million.

  • Lineage Cell Therapeutics' Operating Expenses fell 2.00% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.0 million, marking a year-over-year increase of 47.46%. This contributed to the annual value of $31.0 million for FY2024, which is 8.02% down from last year.
  • Lineage Cell Therapeutics' Operating Expenses amounted to $31.0 million in FY2024, which was down 8.02% from $33.7 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Operating Expenses high stood at $52.1 million for FY2021, and its period low was $27.9 million during FY2020.
  • Over the past 3 years, Lineage Cell Therapeutics' median Operating Expenses value was $33.7 million (recorded in 2023), while the average stood at $33.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 33.57% in 2020, then spiked by 86.91% in 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Expenses (Yearly) stood at $27.9 million in 2020, then surged by 86.91% to $52.1 million in 2021, then declined by 29.99% to $36.5 million in 2022, then decreased by 7.72% to $33.7 million in 2023, then dropped by 8.02% to $31.0 million in 2024.